VENCLEXTA (ven-KLEKS-tuh) is a prescription medicine that is approved to treat people with chronic lymphocytic leukemia (CLL) with 17p deletion, who have received at least one prior treatment. It is not known if VENCLEXTA is safe and effective in children.
- VENCLEXTA is an oral medication that you take once a day
- VENCLEXTA was studied in
a clinical trial of people with previously treated CLL with
17p deletion. 17p deletion is a type of
- VENCLEXTA works differently than other medications. VENCLEXTA targets a specific protein in your body called BCL-2
- VENCLEXTA may cause side effects
What is relapsed or refractory CLL?
Chronic lymphocytic leukemia, or CLL, is a blood cancer that affects your B cells, which may also be called B lymphocytes. B cells are a type of white blood cell that helps your body fight infection. When you have CLL, your abnormal B cells grow and build up in your blood and bone marrow. Over time, these cells can also accumulate in your lymph nodes, spleen, and liver.
Since you have already received at least one other therapy and your cancer either progressed or did not respond to CLL treatment, your doctor may use terms such as relapsed or refractory CLL.
You may have heard the term 17p deletion from your doctor as a way to describe CLL. 17p deletion is a genetic change or mutation in which part of chromosome 17 is missing in some CLL cells. VENCLEXTA is approved for previously treated CLL patients with 17p deletion.
Ask your doctor if you have been tested for 17p deletion.